ArticleHeliyon2024
Integrated network pharmacology and molecular docking to investigate the potential mechanism of Tufuling on Alzheimer's disease.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrating Molecular Analysis and the Pharmacology Network to Discover the Antioxidative Effects ofPlants (Basel, Switzerland) · 2026Article
- Shexiang Tongxin Dripping Pills regulates SOD/TNF-α/IL-6 pathway to inhibit inflammation and oxidative stress to improve myocardial ischemia-reperfusion injury in mice.Frontiers in cardiovascular medicine · 2025Article
- Bioactive Compound Chemistry and Antiasthmatic Activity of Betulinic Acid and Taraxerol in Experimental Models.Current topics in medicinal chemistry · 2025Article
- Proteomic analysis of the sponge Aggregation Factor implicates an ancient toolkit for allorecognition and adhesion in animals.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the mechanism of Tu Fu Ling in treating Alzheimer's disease (AD) using network pharmacology and molecular docking. Methods: The TCMSP and Swiss target prediction databases were utilized to confirm the active components of Tu Fu Ling and their corresponding targets, with target gene names converted using the UniProt database. Genes related to AD were collected from DisGeNET, GeneCards, and the Open Target Platform databases. Common target genes between the disease and the drug were obtained using Venny 2.1 tools and visualized using Cytoscape software. Protein-protein interaction (PPI) data were further analyzed to determine correlations between common target genes, and GO and KEGG pathway enrichment analyses were performed for intersecting genes. Finally, PYmol, AutoDock Tool, Discovery Studio 2020, and PyRx software were used for preliminary computer virtual verification and visualization of active drug ingredients and target proteins. Results: Nine active ingredients meeting the screening criteria yielded a total of 168 genes after removing duplicates. A total of 3833 target genes were collected, with 129 overlapping target genes identified. GO enrichment analysis identified 643 biological processes, 82 cellular components, and 147 molecular functions. KEGG pathway enrichment analysis also revealed a pathway closely related to AD (hsa05010: Alzheimer's disease). In molecular docking analysis, the binding affinity between the 9 active ingredients and 10 core targets ranged from -3.5 to -12.3 kcal/mol, indicating strong binding. Conclusion: This study preliminarily verified the combination of Tu Fu Ling's screened active ingredient and the calculated core target, suggesting a potential mechanism of action to improve the symptoms of AD patients through multi-target and multi-pathway approaches. This provides a valuable reference for further exploration of the pharmacological mechanism of AD and the formulation of drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.